55453-89-9

Usage

Uses

Used in Pharmaceutical Industry:
BENZENE ACETIC ACID, 4-[(2-CARBOXYPHENYL)METHOXY] is used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of pain, inflammation, and other symptoms associated with various conditions such as arthritis, gout, and migraine.
Used in Pain Management:
BENZENE ACETIC ACID, 4-[(2-CARBOXYPHENYL)METHOXY] is used as an analgesic to alleviate pain caused by various conditions, including musculoskeletal disorders, dental pain, and postoperative pain.
Used in Inflammation Reduction:
BENZENE ACETIC ACID, 4-[(2-CARBOXYPHENYL)METHOXY] is used as an anti-inflammatory agent to reduce inflammation and swelling in conditions such as arthritis and other inflammatory disorders.
Used in Ophthalmology:
BENZENE ACETIC ACID, 4-[(2-CARBOXYPHENYL)METHOXY] is used in the form of eye drops to treat ocular inflammation and pain, particularly in conditions like uveitis and postoperative inflammation following eye surgery.
Used in Topical Application:
BENZENE ACETIC ACID, 4-[(2-CARBOXYPHENYL)METHOXY] is used in the form of topical gels to provide localized pain relief and reduce inflammation in conditions such as sprains, strains, and other musculoskeletal injuries.
Overall, BENZENE ACETIC ACID, 4-[(2-CARBOXYPHENYL)METHOXY] is a versatile compound with a wide range of applications in the pharmaceutical industry, particularly for the management of pain and inflammation. Its availability in various forms, such as oral tablets, eye drops, and topical gels, makes it a convenient and effective option for healthcare professionals to prescribe to patients experiencing pain and inflammation.

InChI:InChI=1S/C16H14O5/c17-15(18)9-11-5-7-13(8-6-11)21-10-12-3-1-2-4-14(12)16(19)20/h1-8H,9-10H2,(H,17,18)(H,19,20)

Upstream product

• 2417-73-4 methyl 2-bromomethylbenzoate 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 
• 87-41-2 2-benzofuran-1(3H)-one 
• 156-38-7 4-hydroxyphenylacetate 
• 1009378-92-0 4-(2-methoxycarbonylbenzyloxy)phenyl acetic acid 
• 34040-62-5 o-(chloromethyl)benzoic acid methyl ester 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 

Downstream Products

• 113806-05-6 olopatadine 
• 113806-06-7 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid 
• 140462-76-6 olopatadine hydrochloride 
• 173677-68-4 N-<2-(6,11-dihydro-11-oxodibenzoxepin-2-yl)ethyl>-N-(phenylmethoxy)-1,1-(dimethylethyl)carbamate 
• 173677-70-8 N-<2-(6,11-dihydro-11-oxodibenzoxepin-2-yl)ethyl>-N-(phenylmethoxy)acetamide 
• 55453-87-7 isoxepac 

Relevant academic research and scientific papers

Preparation method of olopatadine hydrochloride

The method comprises the following steps: [3 - (dimethylamino) propyl] triphenylphosphonium bromide hydrobromide is added into tetrahydrofuran. The sodium hydride and dimethyl sulfoxide are added 11 - oxo -6, 11 - dihydrodibenzo [b, e] oxazepine -2 - acetic acid and stirred until the reaction system forms a black brown suspension reaction. The reaction solution is quenched by a mixed solution of purified water and tetrahydrofuran, and then the aqueous phase is treated with a mixed solvent of hydrochloric acid and n-butanol. The olopatadine hydrochloride is stirred and added with hydrochloric acid to form a white turbid liquid, and then is filtered through stirring after stirring, and is dried to obtain olopatadine hydrochloride, and the prepared oxalolopatadine hydrochloride is high in yield and short in reaction route.

A process for the preparation of olopatadine hydrochloride

The invention relates to a method for preparing a compound, namely, olopatadine hydrochloride. The method specifically comprises the following steps: by taking 2-chloromethyl methyl benzoate and methyl 4-hydroxyphenylacetate as initial raw materials, performing etherification, hydrolysis and cyclization, further performing wittig reaction, and salifying, thereby synthesizing olopatadine hydrochloride. The process is gentle in process reaction condition, acetic anhydride is adopted to replace polyphosphoric acid, a hydrochloric acid organic solvent is adopted to effectively split Z/E type olopatadine so as to obtain olopatadine hydrochloride, conversion of Z/E configuration is effectively achieved after an E configuration byproduct is treated by using concentrated hydrochloric acid, the yield of olopatadine hydrochloride is increased, the product purity is good, and the feasibility of industrialization production is greatly improved.

IMPROVED PROCESS FOR LL-[(Z)-3-(DIMETHYLAMINO)PROPYIIDENEL-6-LL- DIHYDRODIBENZ[B,EL OXEPIN-2-ACETICACID

The present invention relates to an improved process for the preparation of 11- [(Z)-3-(dimethylamino)propylidene]-6, 11 -dihydrodibenzo[b,e]oxepin-2-aceticacid compound of formula- 1 and its pharmaceutically acceptable salts.

2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER AND METHOD FOR PRODUCING THE SAME

Dibenzoxepinacetic acid useful as an intermediate for pharmaceutical products can advantageously be produced by way of a method for producing methyl 2-(4-methoxycarbonylmethylphenoxymethyl)benzoate comprising a reaction of methyl 2-chloromethylbenzoate with methyl 4-hydroxyphenylacetate.

TERTIARY ALKYL ESTER OF OXODIBENZOXEPIN ACETIC ACID

A tertiary alkyl ester represented by Formula (2): wherein R1 and R2 each independently represent a C1-4 alkyl group, and a method for producing the same.

Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof

The present invention provides a novel polymorphic form of olopatadine hydrochloride ([(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride), a selective histamine H1-receptor antagonist that is used for the treatment of ocular symptoms of seasonal allergic conjunctivitis. The present invention also provides novel methods for producing olopatadine on a large scale, and in a manner that is cost effective, provides a low level of impurities and eliminates the need to use the costly and dangerous base, butyllithium, which is used in prior art reactions for making olopatadine. The present invention further provides novel processes for carrying out a large scale production of 3-dimethylaminopropyltriphenylphosphonium bromide and its corresponding hydrobromide salt, which are employed in the production of olopatadine, and pharmaceutically acceptable salts of olopatadine.

Dibenzoxepinone hydroxylamines and hydroxamic acids: Dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity

Hydroxylamine and hydroxamic acid derivatives of a known nonsteroidal antiinflammatory dibenzoxepine series display both cyclooxygenase (CO) and 5- lipoxygenase (5-LO) inhibitory properties. Many of these new dual CO/5-LO inhibitors also exhibit potent topical antiinflammatory activity in the arachidonic acid-induced murine ear edema model. On the basis of their promising profile of in vitro and in vivo activities, hydroxamic acids 24h, 3-(6,11-dihydro-11-oxodibenz[b,e]oxepin-2-yl)-N-hydroxy-N-methylpropanamide (HP 977), and 25, 3-(6,11-dihydrodibenz[b,e]oxepin-2-yl)-N-hydroxy-N- methylpropanamide (P10294), were selected as developmental candidates for the topical treatment of inflammatory skin disorders.

Dibenz[b,e]oxepin compounds

Novel dibenz[b,e]oxepin derivatives are employed in the treatment and control of allergic conditions such as allergic asthma.